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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease affecting the upper and lower motor
neurons in the motor cortex and spinal cord. Abnormal accumulation of mutant superoxide dismutase I
(SOD1) in motor neurons is a pathological hallmark of some forms of the disease. We have shown that the
orderly progression of the disease may be explained by misfolded SOD1 cell-to-cell propagation, which is
reliant upon its active endogenous synthesis. Reducing the levels of SOD1 is therefore a promising
therapeutic approach. Antisense oligonucleotides (ASOs) can efficiently silence proteins with gain-of-
function mutations. However, naked ASOs have a short circulation half-life and are unable to cross the blood
brain barrier (BBB) warranting the use of a drug carrier for effective delivery. In this study, calcium phosphate
lipid coated nanoparticles (CaP-lipid NPs) were developed for delivery of SOD1 ASO to motor neurons. The
most promising nanoparticle formulation (Ca/P ratio of 100:1), had a uniform spherical core-shell
morphology with an average size of 30 nm, and surface charge (ζ -potential) of −4.86 mV. The encapsulation
efficiency of ASO was 48% and stability studies found the particle to be stable over a period of 20 days. In
vitro experiments demonstrated that the negatively charged ASO-loaded CaP-lipid NPs could effectively
deliver SOD1- targeted ASO into a mouse motor neuron-like cell line (NSC-34) through endocytosis and
significantly down-regulated SOD1 expression in HEK293 cells. The CaP-lipid NPs exhibited a pH-
dependant dissociation, suggesting that that the acidification of lysosomes is the likely mechanism responsible
for facilitating intracellular ASO release. To demonstrate tissue specific delivery and localization of these NPs
we performed in vivo microinjections into zebrafish. Successful delivery of these NPs was confirmed for the
zebrafish brain, the blood stream, and the spinal cord. These results suggest that CaP-lipid NPs could be an
effective and safe delivery system for the improved delivery of SOD1 ASOs to motor neurons. Further in vivo
evaluation in transgenic mouse models of SOD1 ALS are therefore warranted.
Disciplines
Medicine and Health Sciences
Publication Details
Chen, L., Watson, C., Morsch, M., Cole, N. J., Chung, R. S., Saunders, D. N., Yerbury, J. J. & Vine, K. L.
(2017). Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons Using Calcium
Phosphate-Lipid Nanoparticles. Frontiers In Neuroscience, 11 476-1-476-12.
Authors
Liyu Chen, Clare A. Watson, Marco Morsch, Nicholas Cole, Roger Chung, Darren N. Saunders, Justin J.
Yerbury, and Kara L. Vine
This journal article is available at Research Online: http://ro.uow.edu.au/ihmri/1115
ORIGINAL RESEARCH
published: 30 August 2017
doi: 10.3389/fnins.2017.00476






Fondazione Santa Lucia (IRCCS), Italy
Jenny Sassone,






These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 01 June 2017
Accepted: 10 August 2017
Published: 30 August 2017
Citation:
Chen L, Watson C, Morsch M,
Cole NJ, Chung RS, Saunders DN,
Yerbury JJ and Vine KL (2017)
Improving the Delivery of SOD1





Improving the Delivery of SOD1
Antisense Oligonucleotides to Motor
Neurons Using Calcium
Phosphate-Lipid Nanoparticles
Liyu Chen 1, 2†, Clare Watson 1, 2†, Marco Morsch 3, Nicholas J. Cole 3, Roger S. Chung 3,
Darren N. Saunders 4, Justin J. Yerbury 2 and Kara L. Vine 1, 2*
1 Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia, 2 Science Medicine and Health Faculty, Centre
for Medical and Molecular Bioscience, School of Biological Sciences, University of Wollongong, Wollongong, NSW, Australia,
3Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW,
Australia, 4 School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease affecting
the upper and lower motor neurons in the motor cortex and spinal cord. Abnormal
accumulation of mutant superoxide dismutase I (SOD1) inmotor neurons is a pathological
hallmark of some forms of the disease. We have shown that the orderly progression
of the disease may be explained by misfolded SOD1 cell-to-cell propagation, which is
reliant upon its active endogenous synthesis. Reducing the levels of SOD1 is therefore a
promising therapeutic approach. Antisense oligonucleotides (ASOs) can efficiently silence
proteins with gain-of-function mutations. However, naked ASOs have a short circulation
half-life and are unable to cross the blood brain barrier (BBB) warranting the use of a drug
carrier for effective delivery. In this study, calcium phosphate lipid coated nanoparticles
(CaP-lipid NPs) were developed for delivery of SOD1 ASO to motor neurons. The
most promising nanoparticle formulation (Ca/P ratio of 100:1), had a uniform spherical
core–shell morphology with an average size of 30 nm, and surface charge (ζ -potential)
of −4.86 mV. The encapsulation efficiency of ASO was 48% and stability studies found
the particle to be stable over a period of 20 days. In vitro experiments demonstrated
that the negatively charged ASO-loaded CaP-lipid NPs could effectively deliver SOD1-
targeted ASO into a mouse motor neuron-like cell line (NSC-34) through endocytosis
and significantly down-regulated SOD1 expression in HEK293 cells. The CaP-lipid
NPs exhibited a pH-dependant dissociation, suggesting that that the acidification of
lysosomes is the likely mechanism responsible for facilitating intracellular ASO release.
To demonstrate tissue specific delivery and localization of these NPs we performed in
vivo microinjections into zebrafish. Successful delivery of these NPs was confirmed for
the zebrafish brain, the blood stream, and the spinal cord. These results suggest that
CaP-lipid NPs could be an effective and safe delivery system for the improved delivery
of SOD1 ASOs to motor neurons. Further in vivo evaluation in transgenic mouse models
of SOD1 ALS are therefore warranted.
Keywords: amyotrophic lateral sclerosis, motor neurone disease, drug delivery, calcium phosphate nanoparticle,
antisense oligonucleotide, SOD1, therapeutic intervention, zebrafish
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an incurable
neurodegenerative disease that is associated with protein
misfolding and aggregation. Accumulation of toxic
proteinaceous aggregates in the upper and lower motor
neurons of the motor cortex and spinal cord over time is
associated with motor neuron death, leading to loss of muscle
control, muscle atrophy, and invariably death (Brettschneider
et al., 2014). The causes of most ALS cases remain undefined,
however ∼5–10% are inherited (Majoor-Krakauer et al., 2003).
Mutations in genes known to cause ALS are growing and include,
FUS/TLS, VAPB, TARDBP, OPTN, VCP, SQSTM1, UBQLN2,
CCNF, PFN1, MATR3, and hexanucleotide repeat expansions
in C9ORF72 (Renton et al., 2014). Due to its early discovery in
1993, the best-studied mutation associated with the familial form
of ALS (fALS) is in the gene encoding copper/zinc superoxide
dismutase (Cu/Zn SOD, SOD1) (Rosen et al., 1993).
SOD1 is a 32-kDa homodimeric metalloenzyme, found
primarily in the nucleus, plasma membrane, and cytosol. It
contains an active site that binds a catalytic copper ion and a
structural zinc ion where it serves to catalyze the dismutation
of superoxide radical to dioxygen and hydrogen peroxide (Perry
et al., 2010). The correctly folded and active form of the
SOD1 enzyme is obtained through several post-translational
modifications such as the acquisition of zinc and copper ions,
disulfide bond formation, and dimerization (Arnesano et al.,
2004). However, mutations that lead to the dissociation of metal
ions, and reduction of the intramolecular disulfide bond are
known to decrease its conformational stability and promote
misfolding. It is well accepted that mutations in SOD1 cause ALS
through a toxic gain of function rather than a loss of its native
function. Over 180 mutations in the SOD1 gene that impact upon
its structural stability have now been identified (http://alsod.iop.
kcl.ac.uk/Overview/gene.aspx?gene_id=SOD1).
A common pathological hallmark in SOD1-ALS cases is the
abnormal accumulation of mutant SOD1 in motor neurons of
the affected nervous tissues. Our group has recently reported that
misfolded SOD1 is present in sporadic disease as well as SOD1-
linked fALS, and can propagate cell-to-cell in a prion-like fashion
potentially contributing to the orderly progression of the disease
(Grad et al., 2014). In addition, we have shown that this cell-
to-cell transmission of SOD1 protein aggregates is dependent
on fluid-phase endocytosis pathways, primarily via stimulated
macropinocytosis (Zeineddine et al., 2015), and relies on active
SOD1 synthesis and its presence in a form readily incorporated
into aggregates in recipient cells (Grad et al., 2014). Reducing
the levels of monomeric and/or misfolded SOD1 is therefore a
promising therapeutic target for familial and potentially some
sporadic SOD1-related forms of ALS.
Considering the key role copper plays in regulating SOD1
protein stability and function and that low levels have been
associated with SOD1 misfolding (Bourassa et al., 2014), a novel
ALS treatment based on the concept of copper supplementation
to motor neurons has recently been suggested. In the SOD1G93A
transgenic mouse model of ALS, the administration of CuATSM,
a compound capable of transporting copper into the brain,
extended the lives of ALS rodents by 18 months (Soon et al.,
2011). Furthermore, restoring copper homeostasis with CuATSM
treatment was found to rescue neurons from their symptomatic
stage. The effect of CuATSM in patients with familial SOD1-
ALS is currently being examined in a Phase I clinical trial
(NCT03136809). Another approach currently under clinical
investigation involves intraventricular or intrathecal delivery of
antisense oligonucleotide against SOD1 for patients with SOD1
fALS (Smith et al., 2006). In a Phase I, randomized, first-in-man
study, Miller et al. reported a reduction of SOD1 concentrations
in brain tissue, and that this correlates with reduced SOD1 in the
CSF (Miller et al., 2013). Although these data strongly support
use of SOD1 antisense oligonucleotide as a therapy, the route of
administration is invasive by nature and poses a greater risk of
post-surgery complications, particularly for repeat dosing.
Nanomedicine is a rapidly growing field that has produced
several drug delivery vehicles, such as lipid and polymeric-based
nanoparticles, able to deliver genes, and other therapeutics to
tissues including the brain and spinal cord (Soppimath et al.,
2001; Vieira and Gamarra, 2016). Mechanistically, a drug poorly
distributed to the brain can be loaded on/into a nanocarrier
system which interacts with the endothelial cells at the blood
brain barrier (BBB) to produce higher drug concentrations in
brain parenchyma. These nanocarriers can be further modified
with targeting moieties to preferentially bind to putative
receptors or transporters expressed at the BBB for enhanced
CNS selectivity, permeability, and drug trafficking. For example,
liposomes surface functionalized with apoE fragments, folate,
transferrin or anti-transferrin receptor (anti-TfR) antibody have
been shown to cross the BBB by transcytosis and deliver genes
to the nervous system, including neurons, with little toxicity
(Mc Carthy et al., 2015). In ALS, only one preclinical study
has used nanoparticles (glutathione functionalized liposomes) to
transport a drug across the BBB, and increase its availability in
the CNS, but disappointingly failed to deliver cargo into neurons
(Evans et al., 2014). Herein we report the manufacture and
biophysical characterization of solid core calcium phosphate lipid
nanoparticles (CaP-lipid NPs) that can encapsulate antisense
oligonucleotide directed to SOD1 (Figure 1A). We also describe
for the first time nanoparticle distribution in the brain, spinal
cord, and blood circulation of zebrafish, a powerful experimental
vertebrate model for studying ALS. We propose that CaP-




Cholesterol, dioleoylphosphatydic acid (DOPA), 1,2-dioleoyl-
3-trimethylammonium-propane chloride salt (DOTAP),
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
(lissaminerhodamine B sulfonyl) (ammonium salt) (LissRdB-
DSPE), and 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-
N-[methoxy-(polyethyleneglycol-2000) ammonium salt
(DSPE-PEG) were purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL). All other chemicals were obtained from
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FIGURE 1 | Physical properties of SOD1-ASO-loaded CaP-lipid NPs with a
Ca/P ratio 100:1. Schematic representation of SOD1-ASO loaded CaP-lipid
NP formulation (A), particle size (d.nm) of SOD1-ASO loaded (black) and
non-loaded (red) CaP-lipid NPs determined by DLS (B), zeta potential of
SOD1-ASO CaP-lipid NP (C), transmission electron micrograph (TEM) of
SOD1-ASO CaP-lipid NPs visualized by negative staining (D), pH-sensitivity as
indicated by change in number size (d.nm) of CaP-lipid NPs in PBS at pH 7.4,
6.5, and 5.0 following incubation at 37◦C for up to 4 h (E). **P < 0.01.
Sigma-Aldrich (St. Louis, MO) without further purification.
SOD1 antisense oligonucleotide (target sequence 5′-CCG TCG
CCC TTC AGC ACG CA-3′) (Patent US 20120214865 A1) and
a scrambled negative control oligonucleotide (target sequence
5’-GCC AGC CTA CGA CTC CGC TC-3′) were synthesized
by GeneWorks. The scrambled control sequence was generated




Non-loaded or SOD1 antisense oligonucleotide (ASO)-loaded
calcium phosphate lipid nanoparticles (CaP-lipid NPs) were
prepared as described by Li et al. (Schneider et al., 2012)
with minor modifications. The anionic lipid coating CaP
core were firstly prepared by a water-in-oil micro-emulsion
method. Briefly, 300 µL of 500 mM CaCl2 and 50 µL of
2mg/mL SOD1 antisense oligonucleotide were added in 15 mL
cyclohexane/Igepal CO-520 (70/30 v/v) solution to form a very
well dispersed water-in-oil reverse micro-emulsion. To form
the phosphate phase, 300 µL of 5 mM Na2HPO4 (pH = 9.0),
50µL of 2 mg/mL SOD1 antisense oligonucleotide and 200 µL
of 20 mg/mL dioleoylphosphatydicacid (DOPA) in chloroform
were dispersed in another 15 mL cyclohexane/Igepal solution.
Then, the phosphate phase was added to the calcium phase in a
dropwise manner. The solution was stirred for 20 min to form
the CaP cores encapsulating SOD1 ASO. The micro-emulsion
was divided equally in to two 50 mL falcon tubes for the purpose
of centrifugation. Absolute ethanol (15 mL) was added to each
tube before centrifugation at 9,000 × g for 30 min in Heraeus
Megafuge X3R (Thermo Scientific, USA). The pellet of CaP cores
was washed and rinsed with ethanol 3 times centrifuging as above
each time. The pellet was resuspended in 1 mL chloroform and
stored in a small glass vial for subsequently lipid coating. The
final CaP lipid-coated nanoparticles were prepared by the thin
film hydration method. Briefly, to 500 µL of CaP cores, 50 µL
10mM DOTAP/Cholesterol (1:1) and 50 µL 3 mM DSPE-PEG-
2000 were added. For cellular uptake studies, LissRdB-DSPE
(12.5µL of a 16 mM stock solution) was also added. The solution
was transferred to a round bottom flask and the chloroform was
evaporated off using a rotary evaporator (Büchi, Switzerland).
Tris-HCl buffer (1 mL; 5 mM; pH 7.4) was then added into
the round bottom flask to rehydrate the lipid film, and the
solution was gently sonicated for 5 min. The final CaP-lipid NPs
were sterile filtered (0.22 µm) and stored at 4◦C for subsequent
characterization and biological evaluation.
Particle Characterization
Zeta (ζ ) potential of CaP-lipid NPs was measured using a
Malvern Zetasizer ZS (Malvern, CA), while size was determined
by dynamic light scattering (DLS) using a Malvern Zetasizer APS
instrument (Malvern, CA). NanoSight (LM14, NanoSight, UK)
was used to calculate particle concentration. Specifically, particles
were diluted to between 108–1010 particles/mL particles (∼1:500
dilution of particles in Milli-Q water) before observing via
conventional optical microscope equipped with a CCD camera
at room temperature. The particle motion (20–100 particles
per field of view) was recorded at 30 frames for 60 s. Particle
concentration was then calculated via the NanoSight software
(NTA 2.3, UK). To visualize the morphology of CaP-lipid NPs we
used transmission electron microscopy (TEM). The nanoparticle
suspension was dropped onto a 200 mesh carbon coated copper
grid and stained with 1% phosphotungstic acid (PTA). The
stained suspension was washed using Milli-Q water and dried at
room temperature before observing on a transmission electron
microscope (TEM; Gantan, Inc.). TEM was carried out using
a JEOL 2010 instrument operating at 200 kV. Bright field
images were captured with an objective aperture inserted to
enhance diffraction contrast. Images were recorded using a Gatan
Orius camera coupled to Gatan’s Digital Micrograph software.
Oligonucleotide loading was determined using the propidium
iodide (PI) staining method whereby the final SOD1 ASO-
loaded CaP-lipid NPs were dissolved in an equal volume of
lysis buffer (2 mM EDTA and 0.05% Triton X-100 in pH 7.8
Tris buffer) and heated at 65◦C for 20 min to release the
entrapped SOD1 ASO for fluorometric measurement. To each
100 µL sample, PI (1µL; 1 µg/µL) was added and fluorescence
(RFLU) was measured using a FLUOstar plate reader (BMG
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Labtech, Germany) (Ex= 540 nm; Em = 620 nm). The amount
of SOD1 ASO loaded into CaP-lipid NPs was then determined
by interpolation of RFLU from a SOD1 ASO standard curve.
The stability of SOD1-loaded CaP-lipid NPs was assessed via the
change in particle size (number peak area) over time measured
by DLS. Briefly, 100 µL SOD1 CaP-lipid NP suspension was
incubated at 4◦C under sterile conditions, and the peak area of
particles measured at the following time points 0, 4, 8, 12, 16,
20, 24, and 28 days. For pH-responsive studies, the particles were
diluted 10 times (v/v) in PBS (pH 7.4, 6.5, or 5), and incubated for
2 and 4 h at 37◦Cwith constant shanking at 200 RPM. The change
in particle size (number peak area) was recorded by DLS. The
corresponding anti-dilution ability was also detected to ensure
that the CaP-NPs retain their size upon dilution in complete
DMEMmedia supplemented with 10% FCS.
Cell Lines and Culture Conditions
The mouse motor neuron-like cell line (NSC-34), a hybrid cell
line produced by fusion of neuroblastoma with mouse motor
neuron-enriched primary spinal cord cell (Cashman et al., 1992),
was routinely cultured in DMEM/F12 supplemented with 10%
(v/v) FBS. The human embryonic kidney (HEK293) cell line,
which has been used extensively as an expression tool to study
recombinant proteins, was cultured in the same media. Cells
were maintained in an incubator at 37◦C under a humidified
atmosphere containing 5% (v/v) CO2. When 80% confluence was
reached, cells were detached by incubation with 5 mM Trypsin-
EDTA and harvested after centrifugation in a Heraeus Megafuge
1.0 (Thermo Scientific, USA) at 1,200 rpm for 5 min at RT. Cells
were resuspended in media, and viable cells counted using a
hemocytometer and trypan blue staining. Cells were confirmed
free of Mycoplasma contamination.
In vitro Cellular Uptake
NSC-34 cells were seeded at 75,000 cells/cm2 into eight well-
chamber slides, and incubated overnight at 37◦C before the
addition of sterile filtered (0.22 µm) non-loaded CaP-lipid
NPs containing LissRdB-DSPE (1:5 or 1:10 v/v). Cells were
then incubated for a further 30, 60, or 90 min at 37◦C to
measure cellular uptake over time. Media was removed and cells
were washed in chilled 1 × PBS before being imaged using a
Leica TCS SPII laser scanning confocal microscope (Heidelberg,
Germany). Internalization was quantified by calculating the
mean fluorescence per cell from five images per treatment using
ImageJ (Schneider et al., 2012). This represents a minimum of
100 cells analyzed per treatment. To confirm the mechanism of
particle uptake, LysoTracker Green DND-26 (Life Technologies,
Mulgrave, VIC) was used to stain for acidic compartments,
lysosomes and endosomes. NSC-34 cells were incubated at 37◦C
with Lysotracker Green DND-26 for 30 min, before the addition
of LissRdB-DSPE CaP-lipid NPs and incubation for a further
30min. Imaging of live cells was carried out as described above.
In vitro Transfection and Gene Silencing
HEK293 cells were seeded in 6-well plates at a density of 20
× 104 cells/well. After reaching 60% confluency, the cells were
treated with SOD1-loaded CaP-lipid NPs, and incubated at 37◦C
for 72 h. Control treatments included non-loaded CaP-lipid NPs,
SOD1 ASO or scrambled negative control with Lipofectamine R©
2,000 Transfection Reagent (ThermoFisher Scientific, Rockford,
IL, USA) and non-loaded CaP-lipid NPs with SOD1 ASO free in
solution. Each treatment delivered an equivalent amount of ASO.
Cells were washed twice with chilled PBS and harvested with
0.05% Trypsin-EDTA. Cell lysates were collected after adding
RIPA lysis buffer (25 mM pH7.6 Tris-HCl, 150 mM NaCl, 1%
Triton X-100, 1% Na-deoxycholate and 1% SDS) supplemented
with HALT Protease Inhibitor Cocktail (1% protease inhibitor
and 1% EDTA; ThermoFisher Scientific). The final protein
extracts were obtained after centrifuging (12,000 × g, 5 min) the
aspirated cell lysates. Total protein concentration in the lysate
was determined by Bio-RAD Assay according to manufacturer’s
instructions using a protein assay kit (Micro BCATM Protein
Assay Kit, Pierce).
Total protein (15 µg) was loaded on a pre-cast sodium
dodecyl sulfate polyacrylamide gel (Bio-Rad, Gladesville, NSW)
and electrophoresed at 150 mV for 45 min. The proteins
were transferred to a pure nitrocellulose blotting membrane
at 1.0A and 25 V for 30 min using the Bio-Rad Trans-
Blot Turbo system. The membrane was blocked with 5%
skim milk in TBST on a horizontal shaker overnight at 4◦C.
The membrane was incubated with 1:1000 sheep polyclonal
antibody to SOD1 (ab8866; Abcam, Melbourne, VIC) for 1 h
at 37◦C on an orbital shaker followed by incubation with
HRP-conjugated donkey anti-sheep IgG secondary antibody
(AB324P; Merck Millipore, Bayswater, VIC) for 1.5 h at room
temperature on a horizontal shaker. Finally, SuperSignal West
Pico Chemiluminescent Substrate (ThermoFisher Scientific) was
added to the membrane and it was exposed using an Amersham
600RGB Imager (GE).
In vivo Delivery and Visualization of CaP
Nanoparticles
Zebrafish (Danio rerio) at an age of 4–6 days post fertilization
(dpf) were used for the injection studies. Experimental
protocols were approved by Macquarie University Animal Ethics
Committee (using zebrafish to understand how the central
nervous system responds to neuronal stress and death caused
by neurodegenerative diseases; protocol no. 2015/033). Zebrafish
were maintained at 28◦C in a 13 h light and 11 h dark cycle.
Embryos were collected by natural spawning and raised at 28.5◦C
in E3 and PTU (1-phenyl-2-thiourea) solution according to
standard protocols (Westerfield, 2000; Morsch et al., 2015). For
in vivo studies, sterile filtered non ASO-loaded CaP-lipid NPs
containing LissRdB-DSPE (stock, 1:5 or 1:10 v/v) were used for
injections into the zebrafish. Borosilicate capillary glass needles
with filament (WPI Inc.) were pulled to a resistance between
2 and 7 M and filled with 4 µL of non-loaded CaP-lipid
NPs containing LissRdB injection solution. A microinjection
apparatus (WPI Inc.; Picospritzer II, General Valve Corporation)
was used under control of a stereo dissection microscope (Leica,
M165FC) to deliver the NPs into the area of interest (∼1–2 nL
per injection). To ensure precise injection anesthetized zebrafish
were mounted into low-melting agarose (Fisher-Scientific) at
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a concentration of 1–1.5% according to established protocols
(Morsch et al., 2017). Control injections were performed with
the same dilution of free LissRdB and fish were imaged under
the same imaging conditions. Imaging was performed at various
time-points (immediately after injections, 2 and 24 h post
injection) using a compound microscope (Leica DMI300b),
a structured illumination microscope (Zeiss ApoTome), or a
confocal microscope (Leica SP5) as described previously (Morsch
et al., 2015). To confirm localization of NPs in the zebrafish
spinal cord and brain, injections were performed into transgenic
lines with fluorescent labeling of neurons [motor neurons:
Tg(-3mnx1:TagBFP); pan-neuronal: Tg(isl1:GFP)] (Don et al.,
2017). Localization in the brain and vasculature was confirmed
with transgenic lines labeling CNS astrocytes [Tg(GFAP:EGFP)]
or the entire vasculature [Tg(fli1a:EGFP)], respectively.
Statistical Analysis
Data are presented as the mean ± standard deviation based
on triplicate values from two or more independent experiments
(n > 6). Student’s t-test or one-way analysis of variance
(ANOVA) using a Tukey’s multiple comparisons post-test were
used to determine statistical significance (GraphPad Prism 6
software). P < 0.05 was considered statistically significant.
RESULTS
Preparation and Characterization of
SOD1-ASO CaP-Lipid Nanoparticles
Previous studies have demonstrated that the stoichiometry of
calcium to phosphate can influence the size, encapsulation
efficiency, and polydispersity of CaP nanoparticles (Olton
et al., 2007; Tang et al., 2015). In this study, the physical
properties of SOD1-ASO CaP-lipid NPs were optimized through
variation of the Ca/P ratio from 20:1 to 100:1, by changing
either the concentration of CaCl2 or Na2HPO4. Particle size
decreased with increasing concentration of CaCl2 (100–500 mM)
(Table 1). Increasing the Ca/P ratio to 200:1 and 400:1, with the
corresponding concentration of CaCl2 at 1000 and 2000 mM,
respectively, lead to poor nanoparticle re-hydration (data not
shown). An inverse trend in particle size was obtained when
increasing the concentration of Na2HPO4 from 5 mM to 25 mM,
whilst keeping the concentration of CaCl2 at 500 mM (Table 1).
The encapsulation efficiency (EE) of ASO was also influenced
by the concentration of CaCl2 and Na2HPO4. We used an
encapsulation method for SOD1-ASO analogous to that reported
by Tang et al. where half of the ASO was mixed with the calcium
and the phosphate solutions to yield a significantly greater EE
than if the ASO was loaded into the calcium or phosphate phases
alone (Tang et al., 2015) (Figure S1). The EE decreased from
69.09 ± 2.7 to 47.87 ± 5.6% when increasing the Ca/P ratio
from 20:1 to 100:1, respectively. However, the difference in EE
between 50:1 and 100:1 Ca/P formulations was not significant
as determined by one-way ANOVA (Table 1). Conversely, the
EE of the SOD1-ASO CaP-NPs peaked at 47.87 ± 2.8% and
displayed a declining trend as the content of Na2HPO4 increased,
when the concentration of CaCl2 was fixed at 500 mM. The EE
appeared to be independent of particle concentration. All ASO-
loaded particles were slightly negatively charged, likely due to the
anionic lipid DOPA in the inner lipid layer and the DSPE-PEG-
2000 in the outer lipid layer which has a net negative charge at pH
7.4. Encapsulation of SOD1 ASO into CaP-lipid NPs with a Ca/P
ratio of 100:1 significantly decreased the zeta potential from−03
± 0.03 to −4.9 ± 0.1 mV. Free SOD1 ASO was −50.1 ± 1.8 mV
(Figure S2). In light of the optimal particle size, concentration
and charge that would be required for crossing the BBB in future
studies, we chose the nanoparticle formulation with a Ca/P ratio
of 100:1 for all subsequent experiments. Full physicochemical
data of this formulation including size, zeta potential, and
morphology using TEM is presented in Figures 1B–D.
pH Sensitivity of CaP-ASO-Nanoparticles
The disassembly of CaP-lipid NPs at low pH allows for the release
of the encapsulated ASO from acidic compartments into the
cytoplasm. The lead CaP-lipid NP formulation (Ca/P ratio of
100:1) displayed pH-dependant dissolution after 4 h (Figure 1E).
No significant difference in particle size was observed when the
particles were incubated at 37◦C in PBS at pH 7.4, and pH 6.5,
however, particle size increased sharply to 84.8 nm 4 h post
incubation at pH 5, indicating particle disassembly. The results
suggest that CaP-lipid NPs exhibit good pH-responsive release
of cargo under acidic conditions with sufficient incubation time.
Stability studies found the particles to be stable in Tris buffer
over a period of 20 days (Figure S3). With respect to the
stability of particles upon dilution, which would occur if using
a systemic route of administration, the CaP-lipid NPs exhibited
a robust anti-dilution effect. No significant change in particle
size was detected when CaP-lipid NPs were diluted 1:10 and
1:50 in complete DMEM supplemented with 10% FCS (Figure
S4), indicating the as-prepared CaP-lipid NPs are likely to retain
colloidal stability in circulation when delivered systemically in
future in vivo studies.
CaP-Lipid Nanoparticle Uptake into
NSC-34 Motor Neuron-Like Cells Is Time
Dependent
It is well known that CaP NPs in the size range of 25–
40 nm can be internalized by various cell lines (Li et al.,
2012; Tang et al., 2015). Here we sought to determine if our
CaP-lipid NPs could be internalized by motor neuron-like
cells. Nanoparticles containing LissRdB-DSPE were added to
the media of NSC-34 motor neuron-like cells at two dilutions
(1:5 or 1:10, total particle concentration 2.69 × 1011.mL−1 and
1.35 × 1011.mL−1, respectively). The fluorescent properties of
LissRdB-DSPE allowed us to monitor uptake of the nanoparticles
in live cells. Following incubation for 30–60 min, confocal
microscopy confirmed close association of our nanoparticles
with NSC-34 cells (Figures 2A,C), indicating that nanoparticles
were entering the cytoplasm, and accumulating in florescent
foci, but were absent in the nucleus (Figure 2). There was
minimal auto fluorescence from NSC-34 cells (Figure 2C,
Figure S5), allowing us to easily distinguish, and quantify
cellular uptake of fluorescent CaP-lipid NPs. After 30 min,
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TABLE 1 | Particle size, Zeta (ζ )-potential, polydispersity index, and encapsulation effiency of SOD1 antisense oligonucleotide calcium phosphate-lipid nanoparticles
(SOD1-ASO CaP-lipid NPs) prepared at different CaCl2, and Na2HPO4 concentrations.
CaCl2 (mM) 100 250 500 500 500
Na2HPO4 (mM) 5 5 5 10 25
CaP Ratio 20/1 50/1 100/1 1/50 1/20
No. Size (nm) 61.0 ± 13.7 52.3 ± 14.7 31.0 ± 2.2 39.9 ± 3.3 50.4 ± 7.6
Zeta Potential (mV) −6.3 ± 0.2 −7.2 ± 0.2 −4.9 ± 0.1 −6.6 ± 0.51 −6.4 ± 0.25
Polydispersity Index (PDI) 0.2 ± 0.019 0.2 ± 0.005 0.3 ± 0.006 0.2 ± 0.014 0.2 ± 0.007
Encapsulation Effiencicy (%) 69.1 ± 2.7 51.1 ± 2.56 47.9 ± 5.6 34.3 ± 4.15 16.1 ± 2.07
Particle Concentration (per mL) 0.7 E11 2.6 E11 11.9 E11 2.6 E11 5.3 E11
Data is presented as the average ± SD (n = 5).
a proportion of the CaP-lipid NP signal was co-localized to
acidic compartments, late endosomes, and lysosomes (Figure S6).
The uptake of nanoparticles was dependent upon time, with a
significant increase in fluorescence after 90 min of incubation
(Figures 2B,C).
ASO Delivered by CaP Nanoparticles
Decreases SOD1 Levels in vitro
SOD1 ASO infused directly into brains via the lateral ventricle
has been used in preclinical models, including rats, and Rhesus
monkeys (Smith et al., 2006). It has also been shown to
significantly reduce SOD1 levels in human fibroblasts after
transfection (Smith et al., 2006). Here we compared the in vitro
efficacy of SOD1 knockdown by free ASO to our SOD1-
ASO-CaP-lipid NPs. Due to the ASO being directed toward
human SOD1, our knockdown experiments were performed in
the HEK293t cell line as they are human derived. Cells were
incubated with either empty CaP-lipid NPs, empty CaP-lipid NPs
+ free (un-encapsulated) SOD1 ASO, or SOD1-ASO-CaP-lipid
NPs. Compared to empty nanoparticles alone, there was a small
decrease in SOD1 levels after incubation with free SOD1 ASO
(Figure 2D). Incubation with SOD1 ASO encapsulated within
CaP-lipid NPs resulted in an 8× reduction in SOD1 levels,
compared with free SOD1 ASO (Figure 2D). While naked ASO
can enter cells inefficiently and interact withmRNA after infusion
into the CNS (Smith et al., 2006), our data shows a significantly
increased SOD1 knockdown through our CaP-lipid NP drug
delivery system.
In vivo Distribution of CaP-Lipid
Nanoparticles in Zebrafish
To test the delivery of the nanoparticles in vivo we microinjected
small volumes (1–2 nL) of empty CaP-lipid NPs into living
zebrafish larvae. Our CaP-lipid NPs were able to diffuse
throughout the brain, and spinal cord after direct injection.
Injections into the brain, the bloodstream and the spinal
cord resulted in characteristic accumulation of speckle-like
structures (Figures 3, 4) compared to the free fluorescent
reporter (Figure S7). Retro-orbital injections into the zebrafish
eye (Pugach et al., 2009) or injections into the posterior
cardinal vein, representing systemic routes of delivery, resulted
in distinctive uptake of fluorescent NPs into the bloodstream
within minutes after injection (Figures 3A–C). The particles
were detectable with high fluorescence emission within the
vasculature of the zebrafish 2 h post administration (Video S1).
After injection into the zebrafish brain we observed rapid NP
accumulation along the ventricle and throughout the whole
brain (Figure 4B). Injections directly into the spinal cord of
the living zebrafish showed accumulation of the CaP-lipid NPs
around neurons and occasionally co-localized with neuronal
labeling within 2 h of injection (Figure 4A). Altogether, our in
vivo application via microinjections revealed an efficient delivery
method for these nanoparticles in order to test their potential in
disease modification in the future.
DISCUSSION
Gene therapies (mostly antisense oligonucleotides; ASO) are in
use for a range of disorders where increasing or decreasing
the production of a specific gene is of therapeutic benefit.
A number of gene therapies are already in clinical use for
various cancers, Gaucher’s disease and Rheumatoid Arthritis
reviewed in Stein and Castanotto (2017). While there are no
approved gene therapy products on the market for ALS, multiple
oligonucleotide-based compounds are under development for
the treatment of brain disorders by direct delivery inside the BBB.
Notably, the first new central nervous system (CNS)-targeted
oligonucleotide-based drug (nusinersen/Spinraza) was approved
by the US Food and Drug Administration (FDA) in late 2016 for
spinal muscular atrophy (SMA) in pediatric and adult patients
and several compounds are beginning to be trialed in a range of
other neurodegenerative diseases (O’Connor and Boulis, 2015;
Khorkova and Wahlestedt, 2017). So far there have been three
gene therapy clinical trials in ALS based on either expressing
growth factors (VEGF and HGF) or ASOs to knockdown
SOD1 reviewed in Scarrott et al. (2015). To date, clinical
trials in ALS have identified that gene therapies are tolerable,
and safe; however more work is needed to understand the
specific advantages and disadvantages of the delivery methods.
For example, while SOD1 ASOs hold great promise, they are
unable to cross the BBB and as such rely on intraventricular or
intrathecal infusion, an invasive surgical procedure whereby ASO
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FIGURE 2 | Internalization of CaP-lipid NPs into NSC-34 cells and knockdown of SOD1 protein expression in HEK293 cells. The CaP nanoparticles contained
LissRdB-DSPE (Ex = 560 nm; Em = 583 nm) in the outer lipid layer. NSC-34 cells were incubated at 37◦C with LissRdB-DSPE CaP-lipid NPs diluted either 1:5 or
1:10 (v/v) for 30, 60 (A) and 90 min (B). Images were acquired with a 63 × objective (512 × 512 pixels; physical length 246.03 µm × 246.03 µm). Change in average
cell fluorescence over 90 min incubation period (C). Red dotted line represents auto fluorescence of NSC-34 cells for comparison. ***P < 0.001 and #P < 0.05
signifies significant difference compared to respective 30 min data. HEK293 cells were treated with SOD1-ASO CaP-lipid NPs for 72 h at 37◦C (Lane 3). Control
treatments included non-loaded CaP-lipid NPs (Lane 2) and non-loaded CaP-lipid NPs with SOD1-ASO free in solution (Lane 1). Controls using Lipofectamine 2000
Transfection Reagent with SOD1-ASO or scrambled negative SOD1 oligonucleotide are not shown here. The change in SOD1 protein expression (16 kDa) was
visualized sing SuperSignal West Pico Chemiluminescent Substrate and exposed using an Amersham 600RGB Imager (D).
is delivered directly to the CNS. Furthermore, initial clinical trials
involving SOD1 ASO infusion did not reduce SOD1 levels in the
CNS at the dose trialed in humans (Scarrott et al., 2015). In this
study, we encapsulated SOD1 ASO in an optimized formulation
of CaP-lipid NPs and examined their biophysical properties,
effectiveness of ASO delivery in vitro and biodistribution in vivo.
The stoichiometry of calcium to phosphate has been
reported to influence the size, encapsulation efficiency (EE), and
polydispersity of CaP nanoparticles (Olton et al., 2007; Tang
et al., 2015). In this study, the EE decreased as the ratio of
Na2HPO4 increased. This is likely due to the fact that the ionic
crosslinking of negatively charged phosphates of the ASO with
positively charged Ca2+ ions would decrease if more PO3−4
ions were present during the co-precipitation step (Truong-
Le et al., 1999; Uskoković and Uskoković, 2011). In contrast,
the size of the particles varied such that the largest particles
were observed when prepared using the highest, and lowest
ratios of Ca/P, a phenomenon similarly described by Tang et al.
(2015). The smallest particles were made using a Ca/P ratio of
100:1. In general, for optimal cell uptake via receptor mediated
endocytosis, particles should be smaller than the clatherin
coated vesicle size (i.e., <200 nm) (Traub, 2009). Of particular
interest here is that small particle size is always preferred for
brain-drug delivery due to the rigorous restriction of the BBB
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FIGURE 3 | Visualization of CaP-lipid NPs after tail vein injection in transgenic zebrafish. Sterile filtered non ASO-loaded CaP-lipid NPs containing LissRdB-DSPE
(stock, 1:5 or 1:10 v/v) was injected into the vein of zebrafish expressing a green fluorescent reporter in their vasculature (Tg(fli1a:EGFP)). Schematic illustration of the
route of injection (A). Expression of EGFP in transgenic fish highlighting the blood vessels (B). Visualization of CaP-lipid NP in 6-day-old transgenic zebrafish 2 h after
injection (C). Zoomed image of the treated zebrafish from area indicated by white box, showing distribution and accumulation of CaP-lipid NP in and around blood
vessels (D). Overlay of transgenic EGFP expression and CaP-lipid NP distribution (E).
(Silva et al., 2017). In addition, Lockman et al. highlights the
importance of nanoparticle surface charge (ζ -potential) on the
integrity, and crossing of the BBB, with neutral and anionic
nanoparticles preferable over cationic particles as colloidal drug
carriers to the brain (Lockman et al., 2004). Taken together, the
properties of nanoparticle size, charge, encapsulation efficiency,
and polydispersity index (PDI) led us to select the SOD1-ASO
CaP-lipid NPs with Ca/P molar ratio of 100:1 (500 mM CaCl2
and 5 mMNa2HPO4) as our lead formulation.
Previous work has shown that CaP NPs in the size range of
25–40 nm can be efficiently internalized by various cell lines
(Li et al., 2012; Tang et al., 2015). Our results suggest that our
CaP-lipid NPs (31.0 ± 2.2 nm) are rapidly taken up by motor
neuron-like NSC-34 cells in a time and concentration dependent
manner. At least partial overlap with a lysotracker dye suggests
trafficking of the CaP-lipid NPs to acidic compartments, likely
late endosomes and lysosomes (Liu et al., 2014). Our optimized
CaP-lipid NPs were stable in solutions of neutral pH for at
least 20 days, but broke down at pH 5 in as little as 4 h.
Once a CaP NP has dissolved it is thought that the released
calcium and phosphate ions cause changes in osmotic pressure
across the lysosomal membrane causing rupture of the vesicle
(Neumann et al., 2009) and release of the ASO. This principle
has for many years been used to transfect mammalian cells with
plasmid DNA. In this study, the efficiency of ASO delivery in
cell culture was increased through CaP-lipid NP encapsulation,
and resulted in significant reduction in SOD1 protein expression.
This is likely due to the pH sensitivity, lysosomal membrane
rupture, and cytoplasmic delivery of ASO. Importantly, CaP
transfection methods have been successfully used on primary
neurons for decades (Dudek et al., 1997), suggesting that CaP-
lipid NPs are a viable system for the delivery of DNA/RNA
to neurons in the brain. CaP has primarily been used as a
transfection agent because it is inexpensive and easy to use,
biocompatible, bioactive, and can alter the osmotic properties
of the lysosome. While there have been reports that transfection
with CaP can cause large-scale lysosome rupture and subsequent
necrosis (Liu et al., 2014), packaging CaP into nanoparticles
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FIGURE 4 | Visualization of CaP-lipid NPs and neurons in the spinal cord and brain of a 6-dpf zebrafish. Sterile filtered non ASO-loaded CaP-lipid NPs containing
LissRdB-DSPE (red) were micro injected into the zebrafish spinal cord (A) and brain (B). (A) Visualization of CaP- lipid NPs containing LissRdB-DSPE (red; injections)
within the spinal cord neurons (green; transgenic expression) of a 6-day-old transgenic zebrafish. Zoomed image of the treated zebrafish from area indicated by white
box, showing distribution of the CaP-lipid NPs within GFP-expressing spinal cord neurons. (B) Expression of brain-injected CaP-lipid NPs (red) in a transgenic
zebrafish expressing astrocyte-specific GFP [green; Tg(GFAP:GFP)] to highlight the brain-specific delivery of these particles. The bottom image overlays the bright-field
channel for better visualization of the CNS. The schematic inserts in panels depict the orientation of the fish and outline the presented area.
suppresses this toxicity (Neumann et al., 2009), making it safe
for intracellular delivery. Moreover, CaP NPs are thought to
have a high loading capacity when compared to other inorganic
particles, and provide several advantages over viral delivery
systems, including low immunogenicity, and the ability to switch
off or modify therapeutic dose.
Some genetic lesions associated with ALS result in toxic gain-
of-function and have been the traditional targets for genetic
therapeutic strategies (Foust et al., 2013). In particular, the largest
known genetic causes of ALS, mutations in SOD1, and C9ORF72,
are both thought to be gain of toxic function mechanisms,
making genetic knockdown a relevant, and important avenue for
research. Yet this strategy has achieved only modest outcomes
to date in preclinical development. For example, knockdown
of SOD1 using viral delivered shRNA in the SOD1G93A ALS
mouse model found only 8% of neurons had been successfully
targeted in 3 week old mice (Foust et al., 2013). Non-viral vectors
are therefore gaining traction as alternative delivery systems
due to their potential safety advantages, ease of manufacture,
customization, BBB targeting potential, and ability to deliver
all nucleic acid varieties [reviewed in Niidome and Huang
(2002) and Pack et al. (2005)]. The BBB presents both a
physical and electrostatic barrier to limit brain permeation of
therapeutics. Previous work has demonstrated that nanoparticles
can overcome the physical barrier and deliver genes to the
nervous system including neurons, by utilizing transcytosis
pathways when functionalized with various ligands including
apoE fragments, folate, transferrin or anti-transferrin receptor
(anti-TfR) antibodies (Mc Carthy et al., 2015). This surface
functionalization could also be applied to CaP-lipid NPs and
has been successfully demonstrated after i.v. administration in
rodent models (Shi and Pardridge, 2000; Shi et al., 2001; da Cruz
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et al., 2005; Re et al., 2011; Qiao et al., 2012). In ALS preclinical
models, the only nanoparticle so far used has been glutathione
functionalized liposomes that targeted methylprednisolone (a
glucocorticoid) across the BBB, and increased its availability in
the CNS (Evans et al., 2014). Two of the main reasons for a lack
of effective neuroprotective therapy for ALS can be attributed
to a number of key challenges including ineffective targeting
and delivery of therapeutic agents specifically to the diseased
CNS site and/or cell type of interest (Scarrott et al., 2015).
However, targeted delivery across the BBB and concomitant
internalization by cells of the brain, in particular motor neurons
using such nanotechnology has so far not been developed
for ALS.
Zebrafish are emerging as a powerful model organism to study
neurodegenerative diseases. This is primarily due to features
such as experimentally feasible (short) developmental life time,
external fertilization, well established methods of transgenesis,
and importantly transparent bodies that allow imaging of the
living nervous system (Westerfield, 2000; Morsch et al., 2017).
In the context of ALS, zebrafish models have been used to study
familial forms, and recapitulate some aspects of ALS pathology,
including loss of motor neurons (Hogan et al., 2017), making
them a useful system for gene therapy testing. In addition,
the ability to generate compound transgenic zebrafish permits
strategies to track and follow different cell types and different
pathogenic proteins concomitantly, making them a valuable
addition to current model systems for study of ALS. Previous
work has shown the utility of the fluorescently labeled cell
populations and simultaneous delivery of therapeutic cargo
encapsulated in fluorescent nanoparticles (Fenaroli et al., 2014).
The work presented here demonstrates that our CaP-lipid
NPs circulate freely within the bloodstream following systemic
delivery in an experimental zebrafish model and were detectable
immediately after and up to 29 h post injection. This prolonged
circulation time is owed to the hydrophilic nature of PEG within
our formulation. PEGylation of particles is well known to create
a protective water shell around the particle thereby protecting
it against enzymatic degradation, decreasing clearance by the
mononuclear phagocyte system and retarding renal clearance,
increasing the residence time in the bloodstream (Suk et al.,
2016). Finally, our CaP-lipid NPs were able to diffuse throughout
the brain and spinal cord after direct injection, demonstrating
the usefulness of zebrafish in the study of nanoparticle delivery
of therapeutic cargo in ALS. It will be interesting to test the
efficacy of our ASO encapsulated CaP-lipid NPs in zebrafish and
mammalian models of SOD1 ALS in the future. Taken together,
our data suggest that CaP-lipid NPs establish a useful tool to
increase gene therapy delivery, and thus efficacy in ALS.
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